Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. It provides branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel to treat and manage pain and conditions in urology, endocrinology, and oncology. The company also offers non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women?s health, and hypertension markets; and pharmaceutical products in the areas of ADHD, pain, urology, and allergy. In addition, it provides various medical devices comprising AMS 700 MS series, AMS 800 artificial urinary sphincters, GreenLight XPS laser systems, Elevate anterior and posterior pelvic floor repair systems, and Monarc subfascial hammock products in the areas of men?s and women?s health, and prostate health. The company?s products also inc
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||-1.55%||Sales Growth - 4 Quarters||-15.23%||Sales Growth - Q/Q||-10.73%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-2.55%||ROE||-8.7%||ROI||-3.62%|
|Current Ratio||1.55||Quick Ratio||1.37||Long Term Debt/Equity||2.86||Debt Ratio||0.83|
|Gross Margin||49.62%||Operating Margin||-27.98%||Net Profit Margin||-11.54%||Dividend Payout Ratio|
|Cash From Financing Activities||Cash From Investing Activities||996.86 M||Cash From Operating Activities||-930.48 M||Gross Profit||329.86 M|
|Net Profit||-89.81 M||Operating Profit||45.75 M||Total Assets||14.15 B||Total Current Assets||5.33 B|
|Total Current Liabilities||3.44 B||Total Debt||5.39 B||Total Liabilities||10.01 B||Total Revenue||714.13 M|
|High 52 week||18.3||Low 52 week||5.43||Last close||7.8||Last change||4.98%|
|RSI||38.08||Average true range||0.39||Beta||0.73||Volume||2.59 M|
|Simple moving average 20 days||1.04%||Simple moving average 50 days||-9.26%||Simple moving average 200 days||-35.37%|
|Performance Week||9.09%||Performance Month||-2.62%||Performance Quart||-18.41%||Performance Half||-52.35%|
|Performance Year||39.04%||Performance Year-to-date||6.85%||Volatility daily||2.7%||Volatility weekly||6.03%|
|Volatility monthly||12.36%||Volatility yearly||42.82%||Relative Volume||179.67%||Average Volume||3.15 M|
|New High||New Low|
2019-06-10 08:07:56 | See what the IHS Markit Score report has to say about Endo International PLC.
2019-06-08 09:30:01 | Why Is Endo ENDP Down 38.9% Since Last Earnings Report?
2019-06-06 07:30:00 | Nationally Recognized Urologist and Author, Aaron Spitz, MD, Teams Up with Endo Pharmaceuticals' Ask About the Curve Campaign to Encourage Men to Get _In Touch_ With Their Anatomy This Men's Health Month
2019-05-23 12:07:29 | This May Hurt a Little Or a Lot as Opioids Haunt Pharma Bonds
2019-05-22 17:55:43 | Larry Robbins' Top 6 Buys of the 1st Quarter
2019-05-16 10:56:41 | Introducing Endo International NASDAQ:ENDP, The Stock That Tanked 91%
2019-05-16 09:01:36 | Endo International’s 2019 Key Growth Drivers
2019-05-15 17:00:00 | Endo to Participate at RBC Healthcare Conference
2019-05-13 11:42:00 | Why Endo International Shares Are Under Pressure Today
2019-05-10 14:41:06 | Endo ENDP Q1 Earnings & Revenues Beat Estimates
2019-05-10 14:24:18 | Endo International ENDP Q1 2019 Earnings Call Transcript
2019-05-09 18:04:07 | Edited Transcript of ENDP earnings conference call or presentation 9-May-19 11:30am GMT
2019-05-09 08:05:12 | Endo International ENDP Beats Q1 Earnings and Revenue Estimates
2019-05-09 07:46:08 | Endo: 1Q Earnings Snapshot
2019-05-09 07:06:56 | Drugmaker Endo posts narrower first-quarter loss
2019-05-09 06:58:36 | Drugmaker Endo quarterly results beat on robust sales of Xiaflex
2019-05-09 06:30:00 | Endo Reports First-Quarter 2019 Financial Results
2019-05-07 09:40:01 | BioDelivery BDSI Stock Up on Q1 Earnings and Sales Beat
2019-05-07 08:06:43 | See what the IHS Markit Score report has to say about Endo International PLC.
2019-05-03 09:51:01 | What's in Store for Catalyst Pharma CPRX Q1 Earnings?
2019-05-02 12:41:33 | Is Endo International plc ENDP A Good Stock To Buy ?
2019-05-02 10:11:02 | What's in Store for BioDelivery BDSI This Earnings Season?
2019-05-01 17:35:00 | Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product
2019-04-30 08:02:12 | What's in Store for BioSpecifics BSTC This Earnings Season?
2019-04-10 17:00:00 | Endo to Announce First-Quarter 2019 Financial Results
2019-04-09 14:04:01 | When Will Endo International plc NASDAQ:ENDP Breakeven?
2019-04-09 10:51:12 | See what the IHS Markit Score report has to say about Endo International PLC.
2019-04-02 11:55:39 | See what the IHS Markit Score report has to say about Endo International PLC.
2019-04-01 12:38:52 | Drug companies that benefit from the war on opioid addiction
2019-04-01 11:16:28 | Drug companies that benefit from the war on opioid addiction
2019-03-30 09:30:01 | Why Is Endo ENDP Down 26.9% Since Last Earnings Report?
2019-03-27 21:11:00 | Endo International plc Announces Early Tender Results of its Previously Announced Cash Tender Offers and Consent Solicitations for up to $1.5 billion Aggregate Purchase Price of its Outstanding Senior Notes
2019-03-25 16:24:10 | Endo International: Wall Street Ratings Not Very Favorable?
2019-03-19 14:26:06 | Catalyst CPRX Reports Wider Q4 Loss, Focuses on Firdapse
2019-03-15 10:23:02 | BioDelivery BDSI Q4 Earnings In Line, Sales Beat, Stock Up
2019-03-14 20:06:00 | Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes
2019-03-14 11:01:03 | Insys Plunges on Auditor's Concern About Insufficient Funds
2019-03-14 07:54:00 | Endo International plc Announces Debt Refinancing Transactions, Including Cash Tender Offers and Consent Solicitations for up to $1.0 billion Aggregate Purchase Price of its Outstanding Senior Notes
2019-03-14 07:51:00 | Endo International plc Announces Proposed Private Offering Of Senior Secured Notes
2019-03-12 09:35:01 | Is Endo International ENDP a Great Stock for Value Investors?
2019-03-11 13:13:34 | Opioid litigation concerns weigh on pharmaceutical loan borrowers
2019-03-11 10:30:56 | What’s Expected to Drive Endo’s Growth in Fiscal 2019?
2019-03-11 09:00:57 | Comparing Endo’s and Mallinckrodt’s Gross Margin Forecasts